FDA approves new drug for Alzheimer’s disease: ‘Meaningful results’

The U.S. Food and Drug Administration (FDA) has approved a new medication for people with Alzheimer’s disease. 

Eli Lilly’s Kisunla (donanemab) is a once-monthly injection intended for adults with early symptomatic Alzheimer's disease, according to a press release from the company.

Eligible patients include those with mild cognitive impairment (MCI) and those who have mild dementia with confirmed amyloid pathology.

This is the first medication to target amyloid plaques — the proteins that build up in the brains of Alzheimer’s patients, often impairing memory and cognitive function — with evidence to support stopping therapy when amyloid plaques are removed, the release stated.